In this year's ranking, CDP has confirmed Fresenius' classification in the second-highest category B. Fresenius is thus once again one of the leading companies in the health care sector. Companies in categories A and B are characterized by transparency, coordinated climate protection measures and the implementation of corresponding best-practice approaches. CDP is one of the most renowned climate and environmental rankings in the capital market. More than 680 investors use the annual results to evaluate climate protection activities and climate-related risks and opportunities of the companies assessed.

The U.S. Food and Drug Administration (FDA) has approved Fresenius Kabi’s biosimilar Idacio®, a citrate-free formulation of adalimumab. Idacio® (adalimumab) is approved for use in the treatment of chronic autoimmune diseases for all eligible indications of the reference product, Humira®**. 

With Idacio Fresenius Kabi expands its U.S. biosimilars portfolio focused on immunology and oncology. It is the company’s second approved U.S. biosimilar launching from July 2023 in accordance with the relevant patent settlement agreement with Abbvie. 

* Idacio® is a registered trademark of Fresenius Kabi Deutschland GmbH in selected countries
**Humira® is a registered trademark of AbbVie, Inc. 
 

Fresenius has been included again in the Dow Jones Sustainability Index (DJSI Europe). The DJSI Europe index represents the top 20 percent of companies based on S&P Global’s analysis of their economic, environmental, and social performance. Fresenius achieved improvements in many categories, the most significant ones in the areas of Occupational Health and Safety, Climate Strategy, as well as Risk and Crisis Management. 

Fresenius has been included again in the Dow Jones Sustainability Index (DJSI Europe). The DJSI Europe index represents the top 20 percent of companies based on S&P Global’s analysis of their economic, environmental, and social performance. Fresenius achieved improvements in many categories, the most significant ones in the areas of Occupational Health and Safety, Climate Strategy, as well as Risk and Crisis Management. 

Fresenius Kabi introduced Pralatrexate Injection, a drug for the treatment of relapsed or refractory peripheral T-cell lymphoma in the U.S. Fresenius Kabi Pralatrexate Injection is a generic of Folotyn® and is available to customers immediately. It is the newest addition to the company’s injectable oncology medicine portfolio, the largest in U.S. health care. 

*Folotyn® is a registered trademark of Acrotech Biopharma.  
 

Fresenius Kabi introduced Pralatrexate Injection, a drug for the treatment of relapsed or refractory peripheral T-cell lymphoma in the U.S. Fresenius Kabi Pralatrexate Injection is a generic of Folotyn® and is available to customers immediately. It is the newest addition to the company’s injectable oncology medicine portfolio, the largest in U.S. health care. 

*Folotyn® is a registered trademark of Acrotech Biopharma.  
 

Helen Giza (54) has been appointed Chief Executive Officer of Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, with immediate effect. Previously, she was Deputy CEO of Fresenius Medical Care. The Supervisory Board of Fresenius Medical Care Management AG unanimously appointed her to succeed Dr. Carla Kriwet (51), who will leave the company at her own request and by mutual agreement due to strategic differences. Helen Giza will continue to serve as Chief Financial Officer of Fresenius Medical Care until a successor is appointed for this position.

In her capacity as CEO of Fresenius Medical Care, Ms. Helen Giza will also be a member of the Management Board of Fresenius Management SE. Dr. Carla Kriwet has resigned from her position as a member of the Management Board of Fresenius Management SE.

Michael Sen, Chairman of the Fresenius Medical Care Management AG Supervisory Board and CEO of Fresenius, said: “In a fundamentally sound industry Fresenius Medical Care now needs to sharpen its focus on the operational turnaround, further drive performance improvements, and focus on its core. We are delighted that Helen Giza will take over as CEO. She is ideally suited to lead Fresenius Medical Care for what lies ahead. During her tenure with the company, Helen Giza has gained thorough expertise in renal healthcare and has a deep understanding of the company. I am very much looking forward to continuing working with Helen Giza in her new role. On behalf of the Supervisory Board, I would like to thank Carla Kriwet, and we wish her all the best for the future.”

Helen Giza said: “I am honored by the appointment and trust the Supervisory Board has placed in me. The role comes with significant responsibility towards the patients we serve. With the knowledge gained as CFO and Chief Transformation Officer of the company, I feel well placed to sharpen the focus on operational turnaround. I truly believe in Fresenius Medical Care’s mission, its passionate employees and great potential.”

Carla Kriwet said: “In this short time, I have met a fascinating company with a very positive corporate culture that works every day to make patients' lives more worth living. The company has great growth potential and is about to undergo a major transformation. I thank my whole team for the great support and wish the company all the best!“

Helen Giza joined Fresenius Medical Care in 2019 as Chief Financial Officer and took on the additional roles of Deputy CEO and Chief Transformation Officer in 2022 heading the FME25 transformation program. Previously, she was Chief Integration and Divestiture Management Officer at Takeda Pharmaceuticals since 2018. Before joining the Takeda Corporate Executive Team, she served as Chief Financial Officer of Takeda’s U.S. business unit since 2008. Prior to that she held a number of key international finance and controlling positions, amongst others at TAP Pharmaceuticals and Abbott Laboratories. Helen Giza is a U.K. Chartered Certified Accountant and holds a Master of Business Administration from the Kellogg School of Management at Northwestern University in Evanston, Illinois, USA.

Dennis Hofmann has been appointed Head of Global Corporate Communications at Fresenius. He succeeds the previous Head of Communications Matthias Link, who will leave the company after 14 years by mutual agreement end of 2022. In his new role, Dennis Hofmann will report to the CEO, Michael Sen and work closely with him, the Management Board and senior executives on all aspects of strategic communications. Dennis will also be responsible for coordinating relevant strategic comms activities within the Fresenius Group and across different business segments.

“I would like to express my sincere gratitude to Matthias Link for his many years of very successful commitment and service to our company and wish him all the best for his future endeavors. Equally, I am very much looking forward to working with Dennis Hofmann. In Dennis, we gain a proven communications expert with a good understanding of people and issues relevant to the company. His diverse communications experience across industries and surrounding the implementation of transformation processes will further strengthen Fresenius’ positioning as a leading healthcare company and make him an asset to our management team”, said Michael Sen, CEO of Fresenius.

“Now more than ever, communication plays a crucial role on the path to #FutureFresenius. I am honored to lead the communications department of such a great company”, Hofmann said. “Every day, more than 300,000 employees worldwide contribute to improving the quality of life of millions of people. It's a privilege to be part of Fresenius’ mission and I will work with my team to ensure we deliver strong corporate communications support that drives business growth and cultural change.”

Dennis Hofmann took up his position as Head of Global Communications at Fresenius Kabi in September 2022. Previously, he spent several years in senior positions within the communications, marketing, and investor relations fields. Most recently he served as Senior Vice President for Corporate Communications & Investor Relations at Leoni AG in Nuremberg. Prior to that, he spent approximately 18 years at Siemens AG where, in his final four years, he held the position of Corporate Senior Vice President for Global Internal and External Communications.